topic

626 Improving the yeast transformation efficiency for yeast display in antibody development
Jian Chen, George Sun

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A376; DOI: 10.1136/jitc-2020-SITC2020.0626
631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
Dahea Lee, Donggeon Kim, Soomin Ryu, Byoung Chul Lee

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A378-A379; DOI: 10.1136/jitc-2020-SITC2020.0631
61 Tumor mutational burden assessments by two commercial targeted sequencing assays
Ruchi Chaudhary, Gitanjali Vaidya, Meeta Sunil, SM Sakthivel Murugan, VL Ramprasad, Ravi Gupta, Eric Stawiski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A38; DOI: 10.1136/jitc-2020-SITC2020.0061
644 Ocular adverse events associated with programmed death-1 and programmed death ligand-1 immunotherapy
LeAnne Young, Shanda Finnigan, Howard Streicher, Helen Chen, James Murray, H Nida Sen, Elad Sharon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A386-A387; DOI: 10.1136/jitc-2020-SITC2020.0644
646 Evaluating a preclinical model of contact hypersensitivity for skin immune checkpoint toxicity
Barbara Ma, Abhinav Jaiswal, K Sanjana Devi, Qingrong Huang, Joy Hsu, Yong Liu, Niroshana Anandasabapathy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A387-A388; DOI: 10.1136/jitc-2020-SITC2020.0646
647 Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™
Hongjuan Zhang, Daniel He, Mingkun Zhang, Xinhe Feng, Annie An, Cunxiang Ju, Henry Li, Davy Ouyang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A388; DOI: 10.1136/jitc-2020-SITC2020.0647
648 Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors
Kevin Tyan, Joanna Baginska, Martha Brainard, Anita Giobbie-Hurder, Mariano Severgnini, Michael Manos, Rizwan Haq, Elizabeth Buchbinder, Patrick Ott, F Stephen Hodi, Osama Rahma

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A389-A390; DOI: 10.1136/jitc-2020-SITC2020.0648
63 Microsatellite instability/mismatch repair biomarker testing disparities in patients with advanced colorectal cancer: Implications for immune checkpoint inhibitors
Bryan Iorgulescu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A39; DOI: 10.1136/jitc-2020-SITC2020.0063
653 Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release
Gabrielle Leclercq, Helene Haegel, Anneliese Schneider, Estelle Marrer Berger, Antje Walz, Christophe Boetsch, Vesna Pulko, Cristiano Ferlini, Christian Klein

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A391-A392; DOI: 10.1136/jitc-2020-SITC2020.0653
651 Neurological adverse events associated with immune checkpoint inhibitors: Our experience in a tertiary care center
Pablo Alvarez-Ballesteros, Javier Buisan-Catevilla, Alvaro Beltrán-Corbellini, Iñigo Corral-Corral, Javier Pozas-Perez, Victor Albarran-Fernandez, Lucia Sanz-Gomez, Jorge Esteban-Villarrubia, Javier Torres-Jimenez, Jesús Chamorro-Perez, Diana Rosero-Rodriguez, María San Román-Gil, Ainara Soria-Rivas

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A391; DOI: 10.1136/jitc-2020-SITC2020.0651

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages